Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

dogDazeSummer Jan. 16 at 1:31 PM

Good share and highlights osteoporosis/ CNS as addtl modalities C5a could support. “Significantly reduce the amount of hormones and reduce the side effects of infection, osteoporosis.” At present, many C5aR targeted drugs have entered clinical practice: ● Avacopam: the first oral small molecule C5aR antagonist, which has been approved for AAV in many countries; $AMGN ● Vilobelimab: anti-C5a monoclyb, which is urgently authorized by the FDA for severe COVID-19; $IFRX ●KP104: Dual-functional antibody, blocking C5 lysis and C5a binding at the same time, P2.3, Paroxysmal Nocturnal Hemoglobinuria (PNH) and renal diseases such as IgA nephropathy. Kira Phara US, private ●PMX-205: Cyclopeptide small molecules, exploring new indications for skin diseases, Alzheimer's disease, etc. (Alsonex, 2026 1b for ALS trial pending), Australia private. $PFE $BIIB https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-novel-clinical-stage-asset-application-alzheimers

0 · Reply

MoneyGroupLLC Jan. 16 at 11:40 AM

Enter: $BIIB Calls Strike Price: $170 Expiry Date: FEB 06 2026 Buy in Price: $5.80 - $6.09 Sell Price: $12.41 Profit : +114% (Turn every $1 into $2.14) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Dijon02 Jan. 15 at 2:41 PM

$BIIB

0 · Reply

MoneyGroupLLC Jan. 14 at 6:13 PM

Enter: $BIIB Calls Strike Price: $180 Expiry Date: FEB 06 2026 Buy in Price: $6.20 - $12.35 Sell Price: $20.62 Profit : +67% (Turn every $1 into $1.67) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

notreload_ai Jan. 14 at 5:33 PM

$BIIB discloses $222 million charge for research partnerships and licensing agreements, reducing Q4 2025 earnings by $1.26 per share in SEC filing. https://notreload.xyz/biogen-reports-222m-charge-impact-on-q4-2025-earnings/

0 · Reply

AStrokeOfLuck Jan. 14 at 1:19 PM

$BIIB

0 · Reply

SuperGreenToday Jan. 14 at 1:18 PM

$BIIB Share Price: $178.32 Contract Selected: Feb 06, 2026 $180 Calls Buy Zone: $9.45 – $11.67 Target Zone: $17.23 – $21.06 Potential Upside: 72% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LandonCapital Jan. 14 at 1:06 PM

$BIIB https://landoncapital.net/biogen-ceo-is-confident-that-alzheimers-drug-will-give-edge-over-lilly/

0 · Reply

Chartist0_0 Jan. 14 at 9:09 AM

$BIIB so far, a near perfect back test of the break out above the downtrend line.

1 · Reply

BillionerOfKing Jan. 13 at 4:57 PM

$BIIB Current Stock Price: $182.45 Contracts to trade: $180 BIIB Jan 16 2026 Call Entry: $3.70 Exit: $5.64 ROI: 53% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Jan 12, 2026, 7:45 PM EST - 5 days ago

Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:05 AM EST - 5 days ago

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Jan 11, 2026, 2:00 PM EST - 6 days ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

STOK

Jan 5, 2026, 8:00 PM EST - 12 days ago

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Dec 30, 2025, 8:57 AM EST - 18 days ago

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge

Dec 22, 2025, 11:20 AM EST - 26 days ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Dec 9, 2025, 7:00 AM EST - 5 weeks ago

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Dec 8, 2025, 6:30 PM EST - 5 weeks ago

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 5, 2025, 9:00 AM EST - 6 weeks ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

STOK

Dec 5, 2025, 9:00 AM EST - 6 weeks ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 3, 2025, 2:03 PM EST - 6 weeks ago

Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:40 PM EST - 6 weeks ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025, 3:43 PM EST - 6 weeks ago

Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:30 AM EST - 6 weeks ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 6 weeks ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

STOK

Nov 27, 2025, 7:30 PM EST - 7 weeks ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Nov 25, 2025, 7:30 AM EST - 7 weeks ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 24, 2025, 11:17 AM EST - 7 weeks ago

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Nov 24, 2025, 7:30 AM EST - 7 weeks ago

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Nov 24, 2025, 7:30 AM EST - 7 weeks ago

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Nov 24, 2025, 7:25 AM EST - 7 weeks ago

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

NVO

Nov 21, 2025, 1:13 PM EST - 2 months ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY

Nov 20, 2025, 7:30 AM EST - 2 months ago

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD GSK JNJ LLY

Nov 17, 2025, 7:30 AM EST - 2 months ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Nov 17, 2025, 7:30 AM EST - 2 months ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

STOK

Nov 17, 2025, 6:00 AM EST - 2 months ago

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Nov 14, 2025, 4:05 PM EST - 2 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS

Nov 13, 2025, 6:41 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript

Nov 13, 2025, 6:30 PM EST - 2 months ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Nov 10, 2025, 5:01 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript

Nov 3, 2025, 7:30 AM EST - 2 months ago

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oct 30, 2025, 9:16 PM EDT - 2 months ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:40 AM EDT - 2 months ago

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Oct 30, 2025, 6:11 AM EDT - 2 months ago

Biogen trims annual profit forecast on expected hit from R&D-related charges

Oct 26, 2025, 7:30 PM EDT - 2 months ago

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Oct 24, 2025, 8:30 AM EDT - 3 months ago

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Oct 24, 2025, 7:30 AM EDT - 3 months ago

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Oct 22, 2025, 7:30 AM EDT - 3 months ago

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Oct 13, 2025, 7:30 PM EDT - 3 months ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

Oct 9, 2025, 4:30 PM EDT - 3 months ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Oct 9, 2025, 4:30 PM EDT - 3 months ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

STOK

Oct 9, 2025, 10:54 AM EDT - 3 months ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 6, 2025, 4:30 PM EDT - 3 months ago

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BMY GILD

Oct 3, 2025, 8:50 AM EDT - 3 months ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 1, 2025, 5:48 PM EDT - 3 months ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BMY IBB LLY MRK MRNA PFE

Sep 28, 2025, 7:30 PM EDT - 3 months ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Sep 26, 2025, 12:21 PM EDT - 4 months ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

ABBV LLY MRK PFE BMY

dogDazeSummer Jan. 16 at 1:31 PM

0 · Reply

MoneyGroupLLC Jan. 16 at 11:40 AM

0 · Reply

Dijon02 Jan. 15 at 2:41 PM

$BIIB

0 · Reply

MoneyGroupLLC Jan. 14 at 6:13 PM

0 · Reply

notreload_ai Jan. 14 at 5:33 PM

0 · Reply

AStrokeOfLuck Jan. 14 at 1:19 PM

$BIIB

0 · Reply

SuperGreenToday Jan. 14 at 1:18 PM

0 · Reply

LandonCapital Jan. 14 at 1:06 PM

$BIIB https://landoncapital.net/biogen-ceo-is-confident-that-alzheimers-drug-will-give-edge-over-lilly/

0 · Reply

Chartist0_0 Jan. 14 at 9:09 AM

$BIIB so far, a near perfect back test of the break out above the downtrend line.

1 · Reply

BillionerOfKing Jan. 13 at 4:57 PM

0 · Reply

Quantumup Jan. 13 at 12:20 PM

Oppenheimer reiterated $LXEO Outperform-$20 $RCKT $TNYA $LRMR $BIIB VYGR DSGN PTCT Oppenheimer said in its note: We believe yesterday's interim look from LX2020's Phase 1/2 HEROIC study in PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) yielded clear efficacy signals across the high-dose cohorts accompanied by unconcerning safety observations. With shares having closed down 23% vs. a flat XBI, the market may have been looking for a more consistent relationship between PKP2 increase and arrhythmia improvement-but we emphasize that the data remain immature, and look forward to 12-month follow-up results from all high-dose participants in 4Q26. We regard the selloff as having made the shares more attractive in view of LX2006's opportunity in Friedreich's ataxia ($1B+ US peak sales opportunity), which remains the key LXEO investor focus in our view and for which Phase 2 remains on track to begin in 1H.

1 · Reply

MoneyGroupLLC Jan. 13 at 7:32 AM

Enter: $BIIB Calls Strike Price: $185 Expiry Date: FEB 06 2026 Buy in Price: $4.40 - $9.50 Sell Price: $6.78 Profit : +54% (Turn every $1 into $1.54) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

History101 Jan. 12 at 10:23 PM

$CLNN Roth Capital believes $BIIB drug Qalsody (already FDA approved for ALS) is better: "our view is that the magnitude of the NIL effect with CLNN's CNM-Au8 is simply not up there with that obtained by Biogen with Qalsody (already FDA approved), and thus will not ultimately impress the FDA....at 28 weeks Qalsody showed a 55% reduction in plasma NfL,...by contrast CNM Au8 at 24 weeks only had a 3% NfL reduction..

2 · Reply

Quantumup Jan. 12 at 2:29 PM

Stifel in a note to investors said: We think $SLNO's (Buy; $115 PT) pre-print is overall solid, meets what investors were largely hoping to see, and supports Vykat's blockbuster potential. $RYTM $AARD $BIIB Here's what else Stifel had to say:

0 · Reply

MoneyGroupLLC Jan. 11 at 11:43 AM

Enter: $BIIB Calls Strike Price: $190 Expiry Date: FEB 06 2026 Buy in Price: $6.30 - $8.50 Sell Price: $14.43 Profit : +129% (Turn every $1 into $2.29) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

WallStreetBuyDip Jan. 10 at 5:01 AM

$BIIB Massive volume spike on Jan 7 with 2.1M shares traded as price hit $186.91. Followed by a slight decrease in volume on Jan 8 at 1.6M shares traded with a price of $186. Waiting for a lower H% before considering entry.

0 · Reply

macroaxis Jan. 9 at 10:40 PM

$BIIB - Option Volatility Signal: Biogen Pin Risk Easing – Potential Opportunity Ahead https://www.macroaxis.com/stock-options/BIIB/Biogen-Inc?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

dogDazeSummer Jan. 9 at 10:34 PM

6/3/25 $MRK offers $3B *before P3 HS data* $48.50 / share, declined. 9/26/25 Moonlake announces data from (2) P3 HS ‘well powered’ studies conducted in different global regions, closing trade $61.99 9/29/25 opens at $6.97, down 92% due to high placebo in 1 of HS studies. 1/8/26, FDA allows Moonlake to disregard P3 study w high placebo rate. 1/9/26 closed $18.26, Wedbush announces “high likelihood approval”. 1/3 buyout value pre data & pre FDA guidance 1/12/26 ? https://www.fiercebiotech.com/biotech/merck-made-3b-plus-offer-moonlake-and-could-revive-interest-late-phase-biotech-ft Merck $BIIB $AMGN want into HS / C5a/ anti inflammatory w focus on China, aka $IFRX $MLTX “Merck has struck a series of deals to bring molecules discovered in China to Western markets, but Davis dismissed the idea the company is leaning more toward the Asian country than anywhere else. The CEO said “it just happens to be that the recency bias in the last couple of deals” has skewed toward China.

2 · Reply

HScottMatusow Jan. 9 at 10:22 PM

Continued from last post; Self-dealing bs is common place in #Biotech. A deal with $NVS grants upper management here cushy options and a position in NVS, whereas #RHHBY and $BIIB would likely only offer an all cash dissolve deal and no future options for $QURE seniors? Again, read the amended change of control/restructure deal approved in June of this year, a long with this year being the first year the company DID NOT AWARD performance incentive option grants (no awards past march) for hitting arguably, the best data ever seen in neurology? And again, out of the last 20 #biotech acquisitions, only 2 has language exactly like $QURE's, AND BOTH WERE ACQUIRED BY $NVS. Coincidence? LOL!! Does anyone out there ever think anymore for themselves. STOP sniffing and kissing $QURE BOD and CEO ass, they are the bad guys, not the #FDA

1 · Reply

hegdaom Jan. 9 at 9:39 PM

$CAPR Can anyone in two to three coherent sentences share here. Whats the argument for a short case? $PFE $LLY $MRK $BIIB $LLY

2 · Reply

Chartist0_0 Jan. 9 at 12:22 PM

$BIIB this is a stock where wake up early, check the preopen and see it’s up 70$ points.

1 · Reply

MoneyGroupLLC Jan. 9 at 11:44 AM

Enter: $BIIB Calls Strike Price: $188 Expiry Date: JAN 30 2026 Buy in Price: $1.59 - $1.67 Sell Price: $3.39 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Market Cap	24.73B
Revenue (ttm)	9.68B
Net Income (ttm)	1.63B
EPS (ttm)	N/A
PE Ratio	10.11
Forward PE	11.28
Profit Margin	16.87%
Debt to Equity Ratio	0.35

Volume	1,816,500
Avg Vol	2,078,190
Day's Range	N/A - N/A
Shares Out	146.70M
Stochastic %K	3%
Beta	0.13
Analysts	Sell
Price Target	$187.46